ArticleJACC. Case reports2026
Paclitaxel-Associated Coronary Vasospasm With Transient ST-Segment Elevation and Hemodynamic Instability.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPaclitaxel is a widely used chemotherapeutic agent with rare but potentially life-threatening cardiovascular toxicity. CASE SUMMARY: A 58-year-old woman developed chest discomfort and syncopized within minutes of receiving her first paclitaxel infusion for recurrent cervical adenocarcinoma. Electrocardiography demonstrated inferior ST-segment elevation with reciprocal changes concerning for inferior-posterior ST-segment elevation myocardial infarction (STEMI). Despite near-complete electrocardiographic resolution, emergent coronary angiography was pursued and revealed severe diffuse coronary vasospasm without obstructive disease. Administration of intracoronary nitroglycerin resulted in prompt angiographic vasodilation, normalization of electrocardiographic changes, and hemodynamic stabilization. Transthoracic echocardiography demonstrated preserved biventricular systolic function. DISCUSSION: Paclitaxel-associated coronary vasospasm is capable of mimicking a STEMI and requires immediate angiographic assessment despite electrocardiogram resolution, especially when clinical instability is present. TAKE-HOME MESSAGES: Paclitaxel can precipitate abrupt, severe coronary vasospasm with shock physiology. Intracoronary nitroglycerin is a low-risk, high-yield intervention that confirms the diagnosis, excludes alternative STEMI mimics, and provides immediate therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.